

**AMENDMENTS TO THE SPECIFICATION:**

Please amend this application on page 1, line 1, by inserting the following new paragraph:

This is a divisional of Application No. 10/051,168, filed on January 22, 2002, pending, which is incorporated herein by reference.

On page 3, please amend the paragraph bridging lines 13-22 as follows:

Based on these results, it has now been found that a medicament is effective against thrombotic diseases if it comprises an active ~~principle~~ principal that induces an irreversible inactivation or degradation of a collagen receptor on thrombocytes. This active ~~principle~~ principal may be a chemical compound or a monoclonal or polyclonal antibody. A preferred monoclonal antibody is JAQ1 and the preferred collagen receptor is platelet GPVI. If the monoclonal antibody JAQ1 is used it should be a humanized monoclonal antibody JAQ1. The hybridoma cell line secreting JAQ1 has been deposited under DSM ACC 2487 at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH in Braunschweig in accordance with the Budapest Treaty.

On page 4, please amend the paragraph bridging lines 26-35 as follows:

*Chemicals.* Anesthetic drugs xylazine (~~Rompun<sup>®</sup>~~) (ROMPUN<sup>®</sup>) and ketamine (~~Imalgene 1000<sup>®</sup>~~) (IMALGENE 1000<sup>®</sup>) were delivered from Bayer (Leverkusen, Germany) and Merial (Lyon, France), respectively. Immobilized papain (Pierce, Rockford, IL, USA), high molecular weight heparin, ADP, phorbol-12-myristate-13-

acetate (PMA), (all from Sigma, Deisenhofen, Germany), FITC-labeled Annexin V (Boehringer Mannheim, Germany), and collagen (Kollagenreagent Horm, Nycomed, Munich, Germany) were purchased. CRP (GKO-(GPO)<sub>10</sub>-GKOG) (single letter amino acid code where O=hydroxyproline) and convulxin were kindly provided by S.P. Watson (Oxford, U.K.). FITC-labeled convulxin was a generous gift from M. Jandrot-Perrus (Paris, France).

On page 18, please amend the paragraph bridging lines 15-23 as follows:

Thus, it is an object of the present invention to provide a medicament for the protection against thrombotic diseases which comprises an active ~~principle~~principal, preferably an antibody, against a platelet collagen receptor that not only blocks, but irreversibly depletes the target receptor. Such a monoclonal antibody is defined by its binding to the same or a similar epitope of the collagen receptor for thrombocytes as the monoclonal antibody JAQ1. Preferably, as antibody the monoclonal antibody JAQ1 should be used. The preferred collagen receptor is platelet GPVI. Most preferred is a medicament which contains the respective humanized monoclonal antibody for protection ~~again~~against thrombotic diseases.

On page 27, please delete line 5 and insert the following:

#### **Brief Description of the Drawings**

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com